0000939767-17-000003.txt : 20170105
0000939767-17-000003.hdr.sgml : 20170105
20170105202514
ACCESSION NUMBER: 0000939767-17-000003
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170103
FILED AS OF DATE: 20170105
DATE AS OF CHANGE: 20170105
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EXELIXIS, INC.
CENTRAL INDEX KEY: 0000939767
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 043257395
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0102
BUSINESS ADDRESS:
STREET 1: 210 E. GRAND AVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 6508377000
MAIL ADDRESS:
STREET 1: 210 E. GRAND AVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS INC
DATE OF NAME CHANGE: 20000207
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20000106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lamb Peter
CENTRAL INDEX KEY: 0001387306
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30235
FILM NUMBER: 17512636
MAIL ADDRESS:
STREET 1: PO BOX 511, 170 HARBOR WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94083-0511
4
1
wf-form4_148366589849602.xml
FORM 4
X0306
4
2017-01-03
0
0000939767
EXELIXIS, INC.
EXEL
0001387306
Lamb Peter
C/O EXELIXIS, INC.
210 E. GRAND AVE.
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
EVP, Scientific Strategy & CSO
Common Stock
2017-01-03
4
M
0
10000
4.42
A
83600
D
Common Stock
2017-01-03
4
M
0
60000
5.96
A
143600
D
Common Stock
2017-01-03
4
S
0
67600
14.63
D
76000
D
Common Stock
2017-01-03
4
S
0
2400
15.27
D
73600
D
Common Stock
16024
I
By 401(k)
Option (right to buy)
4.42
2017-01-03
4
M
0
10000
0
D
2010-02-26
2019-02-25
Common Stock
10000.0
0
D
Option (right to buy)
5.96
2017-01-03
4
M
0
60000
0
D
2010-09-01
2019-08-31
Common Stock
60000.0
15000
D
Includes 16,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 27, 2016.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $14.24 to $15.23. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.24 to $15.32. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4.
Represents 16,024 shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of January 3, 2017.
The option, representing the right to purchase a total of 25,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 26, 2013.
The option, representing the right to purchase a total of 75,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 1, 2013.
/s/ Jeffrey J. Hessekiel, Attorney in Fact
2017-01-05